The ReNEW trial will assess elamipretide for treating patients with dry age-related macular degeneration. Credit: aslysun / Shutterstock.

Stealth BioTherapeutics has enrolled the first subject in the Phase III ReNEW clinical trial as part of a clinical programme to assess elamipretide for treating patients with dry age-related macular degeneration (AMD).

The randomised, double-masked, placebo-controlled ReNEW trial will evaluate the efficacy, safety, and pharmacokinetics of once-a-day doses of elamipretide given as subcutaneous injections.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It will involve 360 patients who will receive either a 40mg dose of elamipretide or a placebo for 96 weeks.

Participants in the ReNEW trial have the opportunity to join a Phase III open-label extension trial, ReTAIN, upon completion.

The ReNEW trial is part of a larger programme that includes the ReGAIN trial, which similarly investigates the daily subcutaneous administration of elamipretide in subjects with dry AMD.

The rate of change in the macular area of photoreceptor loss is the primary efficacy endpoint for both trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This will be measured by spectral domain optical coherence tomography (SD-OCT) and ellipsoid zone mapping at the 48-week mark.

Stealth BioTherapeutics CEO Reenie McCarthy said: “Enrolling the first patient in our Phase III programme puts us one step closer to bringing a potential first-in-class, at-home treatment option to patients living with dry AMD.

“With multiple sites now active and able to enrol patients in the US, we are off to a great start and look forward to evaluating the efficacy and safety of elamipretide in patients with dry AMD in these pivotal Phase III trials.”

In February 2021, Stealth BioTherapeutics completed subject enrolment in the Phase II ReCLAIM-2 study (SPIAM-202) of elamipretide in patients with dry AMD with geographic atrophy.